查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1708157

急性細菌性皮膚和皮膚結構感染 (ABSSI) 市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

Acute Bacterial Skin and Skin Structure Infections (ABSSIs) Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年，全球急性細菌性皮膚和皮膚結構感染市場規模達到 13 億美元，預計 2025 年至 2034 年期間的複合年成長率為 5%。受細菌抗藥性上升、皮膚和軟組織感染盛行率上升以及抗生素配方和給藥方法的快速進步的推動，市場有望穩步成長。越來越多的免疫功能低下的人，包括接受化療或器官移植的患者，對有效治療方案的需求不斷增加。糖尿病和周邊血管疾病等慢性疾病的激增使患者更容易受到複雜的皮膚感染，這進一步支持了市場擴張。

急性細菌性皮膚和皮膚結構感染 (ABSSI) 市場 - IMG1

此外，人們對皮膚感染早期診斷和治療的認知不斷提高，加上針對抗藥性病原體的創新療法的開發，正在極大地影響市場前景。製藥公司正在大力投資研發，以推出能夠對抗 MRSA（耐甲氧西林金黃色葡萄球菌）等多重抗藥性細菌的新型抗生素，這種細菌仍然是全球關注的一大議題。這導致了更先進的抗生素的引入，包括糖肽、噁唑烷酮和脂肽，它們可以針對抗藥性細菌採取針對性行動，改善患者的治療效果並提高治療成功率。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 13億美元
預測值 21億美元
複合年成長率 5%

根據感染類型，市場主要分為兩類：社區獲得性 ABSSSI 和醫院獲得性 ABSSSI。 2024 年，社區型感染佔比高達 64.3%，因為這些感染在一般人群中更為普遍，並且經常發生在醫院環境之外。蜂窩性組織炎、傷口感染和膿腫等病症是每年病例數的重要原因。這些感染經常需要醫療干預，但通常在門診進行治療，因此對有效且易於管理的抗生素療法的需求持續存在。隨著生活方式疾病導致的皮膚損傷和皮膚完整性受損的發生率不斷上升，社區獲得性部分繼續推動 ABSSSI 市場顯著成長。

根據給藥途徑，市場分為腸外給藥、口服給藥及外用給藥。預計到 2034 年，腸外給藥領域將創造 10 億美元的收入，繼續保持其作為抗生素輸送首選途徑的地位，尤其是在嚴重和複雜的情況下。腸外給藥將抗生素直接輸送到血液中，對於治療由多重抗藥性病原體引起的危及生命的 ABSSSI 仍然至關重要。它能夠快速發揮治療作用，對於醫院內感染和重症監護病房的患者尤其重要，因為及時干預對於避免全身性併發症至關重要。

2024 年，美國急性細菌性皮膚和皮膚結構感染 (ABSSSI) 市場價值為 4.763 億美元，這主要是由於皮膚感染發病率高以及糖尿病和肥胖症等慢性健康狀況的增加，這增加了 ABSSSI 的風險。人口老化導致免疫防禦能力下降，更容易發生皮膚感染，這繼續影響市場動態。此外，耐多藥細菌（尤其是抗甲氧西林金黃色葡萄球菌）帶來的持續挑戰，維持了對先進的下一代抗生素療法的需求，並支持了美國市場的持續成長

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

  • 產業生態系統分析
  • 產業衝擊力
    • 成長動力
      • ABSSSI 發生率不斷上升
      • 抗生素研發取得進展，研發藥物數量不斷增加
      • 醫療保健投資不斷增加，醫療服務可近性不斷改善
    • 產業陷阱與挑戰
      • 新型抗生素成本高昂
      • 與某些抗生素相關的副作用
  • 成長潛力分析
  • 監管格局
  • 管道分析
  • 波特的分析
  • PESTEL分析

第4章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 策略儀表板

第5章：市場估計與預測：依感染類型，2021 年至 2034 年

  • 主要趨勢
  • 社區型 ABSSSI
  • 醫院獲得性ABSSSI

第6章：市場估計與預測：依藥物類別，2021 年至 2034 年

  • 主要趨勢
  • 醣肽/脂糖肽
  • 噁唑烷酮
  • BETA-內醯胺類
  • 脂肽
  • 四環素類
  • 其他藥物類別

第7章：市場估計與預測：依管理路線，2021 年至 2034 年

  • 主要趨勢
  • 腸外
  • 口服
  • 外用

第8章：市場估計與預測：按配銷通路，2021 年至 2034 年

  • 主要趨勢
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第9章：市場估計與預測：按地區，2021 年至 2034 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第10章：公司簡介

  • AbbVie
  • Basilea Pharmaceutica
  • Cipher Pharmaceuticals
  • Endo Pharmaceuticals
  • Glenmark Pharmaceuticals
  • Melinta Therapeutics
  • Menarini Group
  • Merck
  • Nabriva Therapeutics
  • Paratek Pharmaceuticals
  • Pfizer
  • Sandoz
簡介目錄
Product Code: 13292

The Global Acute Bacterial Skin and Skin Structure Infections Market reached USD 1.3 billion in 2024 and is projected to expand at a CAGR of 5% between 2025 and 2034. The market is poised for steady growth, driven by rising bacterial resistance, the increasing prevalence of skin and soft tissue infections, and rapid advancements in antibiotic formulations and delivery methods. A growing number of immunocompromised individuals, including patients undergoing chemotherapy or organ transplantation, are contributing to the escalating demand for effective treatment options. The surge in chronic diseases such as diabetes and peripheral vascular disorders, which make patients more susceptible to complicated skin infections, is further supporting market expansion.

Acute Bacterial Skin and Skin Structure Infections (ABSSIs) Market - IMG1

Additionally, growing awareness regarding early diagnosis and treatment of skin infections, coupled with the development of innovative therapies targeting resistant pathogens, is significantly shaping the market outlook. Pharmaceutical companies are investing heavily in research and development to launch novel antibiotics capable of tackling multidrug-resistant organisms like MRSA (Methicillin-resistant Staphylococcus aureus), which remains a major concern globally. This has led to the introduction of more advanced antibiotics, including glycopeptides, oxazolidinones, and lipopeptides, that offer targeted action against resistant bacteria, improving patient outcomes and enhancing treatment success rates.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$1.3 Billion
Forecast Value$2.1 Billion
CAGR5%

The market is segmented into two primary categories based on infection type: community-acquired and hospital-acquired ABSSSIs. Community-acquired infections accounted for a dominant 64.3% share in 2024, as these infections are far more prevalent in the general population and often occur outside hospital environments. Conditions such as cellulitis, wound infections, and abscesses contribute significantly to the number of cases seen annually. These infections frequently require medical intervention but are typically managed in outpatient settings, creating sustained demand for effective and easily administrable antibiotic therapies. With the rising incidence of skin injuries and compromised skin integrity due to lifestyle diseases, the community-acquired segment continues to drive notable growth in the ABSSSIs market.

Based on drug administration routes, the market is classified into parenteral, oral, and topical formulations. The parenteral segment is projected to generate USD 1 billion by 2034, maintaining its stronghold as the preferred route for delivering antibiotics, especially in severe and complicated cases. Parenteral administration, which delivers antibiotics directly into the bloodstream, remains critical for treating life-threatening ABSSSIs caused by multidrug-resistant pathogens. It enables rapid therapeutic action and is especially vital for hospital-acquired infections and patients in intensive care units, where timely intervention is crucial to avoid systemic complications.

The U.S. Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) market was valued at USD 476.3 million in 2024, largely driven by the high incidence of skin infections and rising chronic health conditions, including diabetes and obesity, which elevate the risk of developing ABSSSIs. An aging population, more prone to skin infections due to weakened immune defenses, continues to influence market dynamics. Moreover, the persistent challenge posed by multidrug-resistant bacteria, particularly MRSA, sustains the demand for advanced, next-generation antibiotic therapies and supports continued market growth in the U.S.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing incidence of ABSSSIs
      • 3.2.1.2 Advancements in antibiotic development and expanding number of pipeline drugs
      • 3.2.1.3 Rising healthcare investments and improved access to medical treatments
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of novel antibiotics
      • 3.2.2.2 Side effects associated with certain antibiotics
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Pipeline analysis
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Infection Type, 2021 – 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Community-acquired ABSSSI
  • 5.3 Hospital- acquired ABSSSI

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 – 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Glycopeptides/lipoglycopeptides
  • 6.3 Oxazolidinones
  • 6.4 Beta-lactams
  • 6.5 Lipopeptide
  • 6.6 Tetracyclines
  • 6.7 Other drug classes

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Parenteral
  • 7.3 Oral
  • 7.4 Topical

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Italy
    • 9.3.5 Spain
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 AbbVie
  • 10.2 Basilea Pharmaceutica
  • 10.3 Cipher Pharmaceuticals
  • 10.4 Endo Pharmaceuticals
  • 10.5 Glenmark Pharmaceuticals
  • 10.6 Melinta Therapeutics
  • 10.7 Menarini Group
  • 10.8 Merck
  • 10.9 Nabriva Therapeutics
  • 10.10 Paratek Pharmaceuticals
  • 10.11 Pfizer
  • 10.12 Sandoz